Frontier Pharma: Alzheimer's Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression
NEW YORK, June 21, 2017 /PRNewswire/ -- Read the full report: http://www.reportlinker.com/p04940092/Frontier-Pharma-Alzheimers-Disease-and-Associated-Indications-Exceptional-Level-of-First-in-Class-Innovation-within-AD-and-Diverse-Range-of-Therapies-in-Development-for-Disorders-Such-as-Anxiety-and-Depression.html
Summary
Alzheimer's disease (AD) is the most common form of dementia - a generalized term used to describe loss of memory and other mental abilities that are severe enough to interfere with daily activities. Symptoms of dementia arise as a result of physical changes in the brain (Alzheimer's Association, 2017b). AD accounts for approximately 60-80% of all cases of dementia. As with all forms of dementia, it is a progressive, neurodegenerative and currently incurable disease, with symptoms worsening over time.
AD is a multi-factorial disease resulting from interacting environmental, lifestyle and genetic factors. However, the greatest risk factor for AD development is advancing age. The vast majority of patients are aged 65 and older at diagnosis, although a small proportion develop AD between the ages of 30 and 64, which is termed early-onset AD.
The prevalence of AD is escalating rapidly, largely as a result of aging populations. This will amplify the already substantial societal and economic costs of the disease over the coming decades. However, despite this large market opportunity, there are no disease-modifying therapies currently available that are capable of halting, reversing or effectively modifying the course of disease progression. Treatment options are extremely limited and can only temporarily slow the worsening of symptoms (Alzheimer's Association, 2017a; Yiannopoulou and Papageorgiou, 2013).
Additionally, many aspects of the disease pathophysiology remain incompletely understood, and these knowledge gaps underlie the poor treatment options currently available to AD patients, and the failed attempts to improve on these therapies in clinical trials.
AD pipeline is large, with 646 products in active development. In addition, the level of first-in-class innovation within the pipeline is exceptionally high - 65.3% of products with a disclosed molecular target have been identified as first-in-class. In comparison, the pipeline for AD-associated indications is smaller and less innovative. There are 272 products in development across the four associated indications, and only 27.7% of those with a disclosed molecular target are first in class. However, the diversity of first-in-class targets identified is greater than that of the AD pipeline.
The deals landscape for AD and AD-associated indications has been fairly active over the past decade. The aggregate deal value for licensing deals reached $13.0 billion, while the aggregate deal value for co-development deals totaled $10.7 billion. Small molecule products and those targeting GPCRs have dominated the landscape in terms of both deal frequency and aggregate value.
The report "Frontier Pharma: Alzheimer's Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression" focuses on AD alongside four key associated behavioral and psychological indications: anxiety, depression, psychosis and insomnia. These four conditions are highly prevalent in AD and contribute substantially to the disease burden.
Moreover, this report allows you to -
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, and diagnosis and treatment options.
- Identify leading products and key unmet needs within the market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for AD, anxiety, depression, psychosis and insomnia. Promising early-stage first-in-class targets are reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.
Scope
Unmet need is extremely high in AD, with behavioral and psychological complications contributing significantly to the disease burden
- What are the most important etiological risk factors and pathophysiological processes implicated in AD?
- What is the current treatment algorithm?
- How common are anxiety, depression, psychosis and insomnia in AD?
The AD pipeline is large and contains a very high proportion of first-in-class product innovation
- Which molecule types and molecular targets are most prominent across AD and its associated indications?
- What are the connections, in terms of first-in-class innovation, between AD and its associated indications?
- Which first-in-class targets are most promising?
- How does the level of first-in-class innovation differ between products in development for anxiety, depression, psychosis and insomnia?
- How does first-in-class target diversity differ by stage of development and molecular target class?
The deals landscape is active and dominated by G-protein coupled receptor (GPCR)-targeting products
- Which indications attract the highest deal values?
- How has deal activity fluctuated over the past decade?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?
Reasons to buy
This report will allow you to -
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, diagnosis and treatment options.
- Identify leading products and key unmet needs within the market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for AD, anxiety, depression, psychosis and insomnia. Promising early-stage first-in-class targets are reviewed in greater detail.
Read the full report: http://www.reportlinker.com/p04940092/Frontier-Pharma-Alzheimers-Disease-and-Associated-Indications-Exceptional-Level-of-First-in-Class-Innovation-within-AD-and-Diverse-Range-of-Therapies-in-Development-for-Disorders-Such-as-Anxiety-and-Depression.html
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article